Pfizer withdraws application to sell drug without prescription after it hits opposition from government panel.

The pharma prevents Teva from selling a cheaper version of its drug Pulmicort--at least for now.

Shares lose most of their value after FDA panel questions 6-year-old study results.

The pharma is being plagued by further generic competition.

An FDA committee's vote on Targanta's oritavancin could have a big impact on drug development.